title: [Indications for integrated surgical treatment of peritoneal carcinomatosis of colorectal origin: experience of the Italian Society of Locoregional Integrated Therapy in Oncology].
abstract: A multicentric prospective study has been carried on 69 patients affected by peritoneal carcinomatosis from colorectal cancer. Patients have been treated by cytoreductive surgery and intraoperative hyperthermic chemoperfusion. CC 0-1 has been achieved in 82%. Major morbidity and mortality was respectively 21.7% and 2.9%. Three years overall survival was 26.7% for all series. Difference in survival evaluating CC 0-1 vs CC 2 patients and PCI < or = 10 vs > 10 was statistically significant. Evaluating only patients CC 0-1 and PCI < or = 10 overall survival rised up to 44.7% at 4 years. A smaller subgroup of patients with a disease-free interval to peritoneal carcinomatosis > or = 2-year showed a 50% disease-free survival at 5 years. In conclusion PCI < or = 10, complete or optimal cytoreduction feasibility and disease-free interval have to be considered for the patients selection to the integrate treatment.
authors.affiliation: SC Chirurgia Generale A, Polo Oncologico, Istituto Regina Elena, Roma.
authors.forename: F
authors.initials: F
authors.lastname: Cavaliere
authors.forename: P
authors.initials: P
authors.lastname: Perri
authors.forename: C R
authors.initials: CR
authors.lastname: Rossi
authors.forename: P L
authors.initials: PL
authors.lastname: Pilati
authors.forename: M
authors.initials: M
authors.lastname: De Simone
authors.forename: M
authors.initials: M
authors.lastname: Vaira
authors.forename: M
authors.initials: M
authors.lastname: Deraco
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005240:Feasibility Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D007430:Intraoperative Care; D016685:Mitomycin / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D011446:Prospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D002945:Cisplatin